Itepekimab Reaches Primary Endpoint in COPD Phase 3 Study

Itepekimab, developed by Sanofi and Regeneron, achieved the primary endpoint in the AERIFY-1 Phase 3 study by significantly reducing moderate to severe exacerbations in former smokers with COPD. The study showed a 27% reduction at week 52. However, the AERIFY-2 study did not meet the same endpoint, despite initial positive results.

Participants received itepekimab every two or four weeks alongside standard COPD therapy. The safety profile was consistent, with adverse event rates comparable to placebo. Serious infections and anti-drug antibody occurrences were minimal.

The companies are analyzing the results and liaising with regulators to determine future steps. Itepekimab is being tested for additional respiratory conditions, highlighting its potential benefits in areas with limited treatment options.